Analysts Lift Ratings and Price Targets as Cencora, Inc. (COR)’s Growth Story Gains Momentum

Cencora, Inc. (NYSE:COR) is one of the champion healthcare stocks to bargain for 2026. On January 29, Morgan Stanley upgraded Cencora Inc. (NYSE:COR) from Equalweight to Overweight and raised its terms people to $400, citing the company’s beardown presumption successful specialty pharmaceuticals and its pending bulk acquisition of OneOncology.

Copyright: dolgachov / 123RF Stock Photo

The steadfast besides highlighted Cencora’s plans to divest non-core assets arsenic a affirmative step, boosting its FY2026 U.S. Healthcare Solutions AOI maturation forecast to 10.8% and International AOI maturation to 7.0%, resulting successful an EPS estimation of $17.63, somewhat supra consensus.

On January 16, Cencora Inc. entered into recognition agreements totaling $4.5 billion. The institution is to leverage the recognition installation to concern the acquisition of OneOncology.

The recognition agreements see a $1.5 cardinal word recognition statement with JPMorgan Chase Bank, consisting of 2 tranches of $500 cardinal and $1.5 billion, maturing successful 2 and 3 years, respectively. It has besides secured a abstracted $3 cardinal word indebtedness installation with Citibank arsenic administrative agent.

Cencora is to usage proceeds from the recognition agreements to wage acquisition information for OneOncology, its debt, and screen different related fees and expenses. Funding nether the agreements is contingent connected the institution completing the acquisition.

Following the recognition agreements, Jefferies upgraded Cencora Inc. (NYSE:COR) to a Buy from a Hold and raised the terms people to $440 from $330. The probe steadfast has besides touted the company’s beardown execution grounds and its accrued semipermanent program arsenic compelling concern factors.

Cencora, Inc. (NYSE:COR) is simply a pharmaceutical solutions institution that connects cause manufacturers with healthcare providers, ensuring harmless and businesslike transportation of medicines and wellness products for humans and animals.

While we admit the imaginable of COR arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.